217 related articles for article (PubMed ID: 31806013)
1. Single-nucleus chromatin accessibility reveals intratumoral epigenetic heterogeneity in IDH1 mutant gliomas.
Al-Ali R; Bauer K; Park JW; Al Abdulla R; Fermi V; von Deimling A; Herold-Mende C; Mallm JP; Herrmann C; Wick W; Turcan Ş
Acta Neuropathol Commun; 2019 Dec; 7(1):201. PubMed ID: 31806013
[TBL] [Abstract][Full Text] [Related]
2. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
[TBL] [Abstract][Full Text] [Related]
3. Advanced imaging parameters improve the prediction of diffuse lower-grade gliomas subtype, IDH mutant with no 1p19q codeletion: added value to the T2/FLAIR mismatch sign.
Lee MK; Park JE; Jo Y; Park SY; Kim SJ; Kim HS
Eur Radiol; 2020 Feb; 30(2):844-854. PubMed ID: 31446467
[TBL] [Abstract][Full Text] [Related]
4. IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas.
Leeper HE; Caron AA; Decker PA; Jenkins RB; Lachance DH; Giannini C
Oncotarget; 2015 Oct; 6(30):30295-305. PubMed ID: 26210286
[TBL] [Abstract][Full Text] [Related]
5. Combining hyperintense FLAIR rim and radiological features in identifying IDH mutant 1p/19q non-codeleted lower-grade glioma.
Li M; Ren X; Chen X; Wang J; Shen S; Jiang H; Yang C; Zhao X; Zhu Q; Cui Y; Lin S
Eur Radiol; 2022 Jun; 32(6):3869-3879. PubMed ID: 35079884
[TBL] [Abstract][Full Text] [Related]
6. Radiogenomic association between the T2-FLAIR mismatch sign and IDH mutation status in adult patients with lower-grade gliomas: an updated systematic review and meta-analysis.
Han Z; Chen Q; Zhang L; Mo X; You J; Chen L; Fang J; Wang F; Jin Z; Zhang S; Zhang B
Eur Radiol; 2022 Aug; 32(8):5339-5352. PubMed ID: 35169897
[TBL] [Abstract][Full Text] [Related]
7. Mathematical Modeling and Mutational Analysis Reveal Optimal Therapy to Prevent Malignant Transformation in Grade II IDH-Mutant Gliomas.
Aoki K; Suzuki H; Yamamoto T; Yamamoto KN; Maeda S; Okuno Y; Ranjit M; Motomura K; Ohka F; Tanahashi K; Hirano M; Nishikawa T; Shimizu H; Kitano Y; Yamaguchi J; Yamazaki S; Nakamura H; Takahashi M; Narita Y; Nakada M; Deguchi S; Mizoguchi M; Momii Y; Muragaki Y; Abe T; Akimoto J; Wakabayashi T; Saito R; Ogawa S; Haeno H; Natsume A
Cancer Res; 2021 Sep; 81(18):4861-4873. PubMed ID: 34333454
[TBL] [Abstract][Full Text] [Related]
8. Increased intratumoral infiltration in IDH wild-type lower-grade gliomas observed with diffusion tensor imaging.
Aliotta E; Batchala PP; Schiff D; Lopes BM; Druzgal JT; Mukherjee S; Patel SH
J Neurooncol; 2019 Nov; 145(2):257-263. PubMed ID: 31531788
[TBL] [Abstract][Full Text] [Related]
9. Automated apparent diffusion coefficient analysis for genotype prediction in lower grade glioma: association with the T2-FLAIR mismatch sign.
Aliotta E; Dutta SW; Feng X; Tustison NJ; Batchala PP; Schiff D; Lopes MB; Jain R; Druzgal TJ; Mukherjee S; Patel SH
J Neurooncol; 2020 Sep; 149(2):325-335. PubMed ID: 32909115
[TBL] [Abstract][Full Text] [Related]
10. Improving Noninvasive Classification of Molecular Subtypes of Adult Gliomas With Diffusion-Weighted MR Imaging: An Externally Validated Machine Learning Algorithm.
Guo Y; Ma Z; Pei D; Duan W; Guo Y; Liu Z; Guan F; Wang Z; Xing A; Guo Z; Luo L; Wang W; Yu B; Zhou J; Ji Y; Yan D; Cheng J; Liu X; Yan J; Zhang Z
J Magn Reson Imaging; 2023 Oct; 58(4):1234-1242. PubMed ID: 36727433
[TBL] [Abstract][Full Text] [Related]
11. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
Chen SC; Lo CM; Wang SH; Su EC
BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas.
Paul Y; Mondal B; Patil V; Somasundaram K
Clin Epigenetics; 2017; 9():32. PubMed ID: 28392842
[TBL] [Abstract][Full Text] [Related]
13. Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas.
Yamauchi T; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Kitagawa Y; Kondo E; Tsushita N; Satomi K; Yoshida A; Ichimura K; Narita Y
Brain Tumor Pathol; 2018 Jul; 35(3):148-158. PubMed ID: 29922974
[TBL] [Abstract][Full Text] [Related]
14. Radiomic features from dynamic susceptibility contrast perfusion-weighted imaging improve the three-class prediction of molecular subtypes in patients with adult diffuse gliomas.
Pei D; Guan F; Hong X; Liu Z; Wang W; Qiu Y; Duan W; Wang M; Sun C; Wang W; Wang X; Guo Y; Wang Z; Liu Z; Xing A; Guo Z; Luo L; Liu X; Cheng J; Zhang B; Zhang Z; Yan J
Eur Radiol; 2023 May; 33(5):3455-3466. PubMed ID: 36853347
[TBL] [Abstract][Full Text] [Related]
15. Conventional MR-based Preoperative Nomograms for Prediction of IDH/1p19q Subtype in Low-Grade Glioma.
Liu Z; Zhang T; Jiang H; Xu W; Zhang J
Acad Radiol; 2019 Aug; 26(8):1062-1070. PubMed ID: 30393056
[TBL] [Abstract][Full Text] [Related]
16. Prediction of
Park YW; Han K; Ahn SS; Bae S; Choi YS; Chang JH; Kim SH; Kang SG; Lee SK
AJNR Am J Neuroradiol; 2018 Jan; 39(1):37-42. PubMed ID: 29122763
[TBL] [Abstract][Full Text] [Related]
17. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
Aoki K; Nakamura H; Suzuki H; Matsuo K; Kataoka K; Shimamura T; Motomura K; Ohka F; Shiina S; Yamamoto T; Nagata Y; Yoshizato T; Mizoguchi M; Abe T; Momii Y; Muragaki Y; Watanabe R; Ito I; Sanada M; Yajima H; Morita N; Takeuchi I; Miyano S; Wakabayashi T; Ogawa S; Natsume A
Neuro Oncol; 2018 Jan; 20(1):66-77. PubMed ID: 29016839
[TBL] [Abstract][Full Text] [Related]
18. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
19. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
20. Whole-Tumor Histogram and Texture Analyses of DTI for Evaluation of
Park YW; Han K; Ahn SS; Choi YS; Chang JH; Kim SH; Kang SG; Kim EH; Lee SK
AJNR Am J Neuroradiol; 2018 Apr; 39(4):693-698. PubMed ID: 29519794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
